TABLE 3.
In vitro susceptibilities of the seven antifungal agents against the most frequent Candida spp. isolated, surveillance program in Monterrey, Mexico, 2004 to 2007
| Species (no. of isolates) | Antifungal compound | MIC (μg/ml)
|
% Resistanta | ||
|---|---|---|---|---|---|
| Range | 50% | 90% | |||
| C. albicans (127) | AMB | 0.06-1 | 0.25 | 1 | 0 |
| FLC | 0.25-64 | 1 | 2 | 0.78 | |
| ITC | 0.06-4 | 0.125 | 1 | 1.6 | |
| VRC | 0.015-1 | 0.06 | 0.06 | 0.78 | |
| PSC | 0.015-1 | 0.06 | 0.06 | ||
| RVC | 0.015-1 | 0.06 | 0.125 | ||
| CAS | 0.015-0.125 | 0.03 | 0.06 | ||
| C. parapsilosis (151) | AMB | 0.125-1 | 1 | 1 | 0 |
| FLC | 0.25-8 | 2 | 4 | 0 | |
| ITC | 0.015-2 | 0.125 | 1 | 0 | |
| VRC | 0.015-1 | 0.06 | 0.06 | 0 | |
| PSC | 0.015-1 | 0.06 | 0.06 | ||
| RVC | 0.015-1 | 0.06 | 0.06 | ||
| CAS | 0.06-2 | 0.25 | 2 | ||
| C. tropicalis (59) | AMB | 0.06-1 | 0.5 | 1 | 0 |
| FLC | 0.5-32 | 2 | 8 | 0 | |
| ITC | 0.03-4 | 0.06 | 1 | 1.6 | |
| VRC | 0.03-1 | 0.06 | 0.125 | 0 | |
| PSC | 0.015-1 | 0.06 | 0.125 | ||
| RVC | 0.03-1 | 0.06 | 0.125 | ||
| CAS | 0.015-0.125 | 0.03 | 0.125 | ||
| C. glabrata (32) | AMB | 0.125-4 | 1 | 4 | 12.5 |
| FLC | 1->64 | 8 | >64 | 31.25 | |
| ITC | 0.125-4 | 0.5 | 4 | 43.3 | |
| VRC | 0.03-1 | 0.125 | 0.25 | 0 | |
| PSC | 0.015-1 | 0.125 | 0.25 | ||
| RVC | 0.03-1 | 0.25 | 0.5 | ||
| CAS | 0.015-0.5 | 0.03 | 0.125 | ||
a
Resistance breakpoints were as follows: the FLC MIC was ≥64 μg/ml; the ITC MIC was ≥1 μg/ml; the AMB MIC was ≥2 μg/ml; and the VRC MIC was ≥4 μg/ml.